| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 7.8 | 7.8 |
| Profit before tax | 1.8 | 1.2 |
| Net income | 1.3 | 0.7 |
| EPS (diluted, $ a share) | $0.16 | $0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +69.5% |
|---|---|
| Revenue, year on year | -0.0% |
| Operating margin | 28.0% |
10-Q filed with the SEC, NYSE: CCEL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cryo Cell International Inc: key numbers
- Share price
- $4.55Close, Nov 16
- Market cap
- $36.7M
- Shares outstanding
- 8.06MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Misc Health & Allied Services, NECSIC 8090
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cryo Cell International Inc
All →Cryo Cell International Shareholder Meeting
Cryo-Cell International held its Annual Meeting of Stockholders on October 27, 2026. Shareholders elected four directors (David Portnoy, Harold Berger, Mark Portnoy, and Daniel Mizrahi), ratified WIPFLI LLC as the independent auditor for fiscal 2026, and approved a non-binding advisory resolution on executive compensation.